The recent failure of aducanumab, a drug being developed to treat Alzheimer's, leaves in its wake substantial financial losses and deep disappointment.
Biogen and Eisai, the two companies testing the experimental medicine, spent nearly $3 billion on the effort. Despite this setback, billions more are being invested in other potential Alzheimer's therapies. Dozens of startups, with funding from venture capitalists and companies like Biogen, are plowing ahead because when it comes to finding a way to delay or prevent Alzheimer's, failure is not an option.
